The Effects of Medical Treatments Used for Benign Prostatic Hyperplasia on Ejaculation

Basit Öğe Kaydı
dc.contributor.authorKayıkçı, Ali
dc.contributor.authorKaçağan, Coşkun
dc.contributor.authorTekin, Ali
dc.date.accessioned2020-04-30T23:33:27Z
dc.date.available2020-04-30T23:33:27Z
dc.date.issued2015
dc.departmentDÜ, Tıp Fakültesi, Cerrahi Tıp Bilimleri Bölümüen_US
dc.descriptionWOS: 000219417400013en_US
dc.description.abstractIn men, significant lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH) requiring treatment increase with aging. Though declining with aging, many individuals in this population sustain their sexual activities. Many drugs commonly used to treat LUTS may have significant adverse effects on sexual functions including ejaculatory function. Among alpha 1 adrenergic receptor (alpha 1-AR) blockers, the most commonly used drugs for treatment of BPH, silodosin and tamsulosin have been associated significantly with ejaculatory dysfunction. Silodosin and tamsulosin lead to ejaculatory problems respectively 32.5 (p<0.0001) and 8.6 times (p=0.006) higher than placebo does. Other drugs in this class such as terazosin, alfuzosin and doxazosin have minimal effects on ejaculation. There seems to be a positive association between development of ejaculatory dysfunction and therapeutic efficacy of the a1-AR blockers. In addition to alterations in libido and penile erection, 5-alpha reductase inhibitors (5ARI) can cause ejaculatory dysfunction. The rate of abnormal ejaculation with finasteride and dutasteride is similar and three times more than placebo (p<0.0001). Abnormal ejaculation is more common with combination therapy of alpha 1-AR blockers and 5ARI than treatment with the individual class of these drugs. In conclusion, treatment with alpha 1-AR blockers, 5ARI or combination of both can cause ejaculatory dysfunction with varying degrees. As this may have a significant impact on quality of life, individuals for whom medical treatment are planned to relieve LUTS due to BPH should be informed and counseled for drug choice.en_US
dc.identifier.doi10.4274/uob.277en_US
dc.identifier.endpage311en_US
dc.identifier.issn2147-2270
dc.identifier.issue4en_US
dc.identifier.startpage308en_US
dc.identifier.urihttps://doi.org/10.4274/uob.277
dc.identifier.urihttps://hdl.handle.net/20.500.12684/4974
dc.identifier.volume14en_US
dc.identifier.wosqualityN/Aen_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.language.isotren_US
dc.publisherGalenos Yayinciliken_US
dc.relation.ispartofUroonkoloji Bulteni-Bulletin Of Urooncologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectBenign prostatic hyperplasiaen_US
dc.subjectalpha 1 adrenergic receptor blockersen_US
dc.subject5 alpha reductase inhibitorsen_US
dc.subjectejaculationen_US
dc.titleThe Effects of Medical Treatments Used for Benign Prostatic Hyperplasia on Ejaculationen_US
dc.typeReview Articleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
4974.pdf
Boyut:
114.37 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
İndir

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
Diğer Yayınlar Koleksiyonu